$599

Novo Highlights CV Risks of Diabetes in Unbranded Campaign Featuring Anthony Anderson; Xeris Q1 ’22 Earnings Update

Two cardiometabolic-related news items have been observed: Novo has launched a new iteration of its “Get Real About Diabetes” campaign focusing on CV risk in T2DM (view article); and Xeris hosted its Q1 ‘22 earnings call (press release). Below, FENIX provides highlights and insights for the respective new items.

This content is for Read Less members only.
Register
Already a member? Log in here